Walid Shalata

50PUBLICATIONS
46CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersLiquid biopsiesCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (50)

|Sep 26, 2026
The Impact of Angiotensin-Converting Enzyme Inhibitors on Immune-Related Adverse Events and Clinical Outcomes in Patients with Metastatic NSCLC.

|Sep 24, 2026
From Rapid Progression to Long-Lasting Complete Response: A Wide Range of Ripretinib Activity for Metastatic GIST-A Real-World Cohort.

|Sep 15, 2026
Correction: Shalata et al. Correlation Between Body Mass Index and Immunotherapy Response in Advanced NSCLC. Cancers 2025, 17, 1149.

|Aug 26, 2026
De Novo Actionable Genomic Alterations in High-Grade Pulmonary Neuroendocrine Carcinomas: Therapeutic Implications of Targeted Treatment.

|Aug 26, 2026
Impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs) on the Efficacy of Immunotherapy in Metastatic NSCLC.

|Jul 28, 2026
Social Network Clustering Analysis for Detection of Associated Genetic Co-Mutations in Patients with Actionable Driver Mutations in NSCLC.

Pageof 9

Frequent Collaborators

22 joint publications

Abed Agbarya

9 joint publications

Keren Rouvinov

4 joint publications

Zoé Gabrielle Attal

4 joint publications

Leonard Saiegh